|Bid||87.32 x 600|
|Ask||87.33 x 400|
|Day's Range||87.16 - 87.53|
|52 Week Range||69.53 - 87.53|
|PE Ratio (TTM)||31.16|
|Forward Dividend & Yield||2.72 (3.13%)|
|1y Target Est||N/A|
Buyouts are the order of the day in the biotechnology sector this week, with a couple of big-name acquisitions dominating market sentiment heading into the US open on Tuesday. Celgene Corporation (NASDAQ:CELG) leads the pack with its just reported acquisition of Juno Therapeutics Inc (NASDAQ:JUNO), while Novartis AG (NYSE:NVS) announced the successful completion of a […] The post Celgene, Novartis Both Report Billion Dollar Buyouts appeared first on Market Exclusive.
Learn about the origins of Johnson & Johnson as the company turns 132 and the health care conglomerate's five largest shareholders.
Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for hegemony in a new field of oncology. Learn why this deal is important to the biotech sector.
Patent expiries and more widespread usage will fuel expected low-to-mid single digit net sales growth in Europe's generic drug market into 2020, says Moody's Investors Service in a report published today. ...
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.
Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.
JNJ stock is currently trading higher than its 50-day moving average of $141.62 and higher than its 200-day moving average of $136.52. Since Johnson & Johnson’s 3Q17 earnings release, JNJ stock has gained ~8.2%. The ongoing restructuring process in its Medical Devices business, new product launches, and its attractive product pipeline are expected by some to further boost investor sentiment and trigger a stock price rise.
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
Focus this week was on Merck's (MRK) data on Keytruda as well as Novartis's updates on Kymriah and its biosimilar efforts.
In 2018, the biotech industry is expected to witness a continuation of last year’s favorable trends. Noteworthy among them was the approval of Novartis’ (NYSE:NVS) Kymriah, the first cell-based gene therapy known as CAR-T therapy, which is an innovative treatment option for cancer. Spark Therapeutics’s Luxturna, the first gene therapy to treat a rare, inherited form of childhood blindness, was also approved last year.
What Could Drive Bristol-Myers Squibb in 2018? In December 2017, the U.S. FDA (Food and Drug Administration) approved Bristol-Myers Squibb’s (BMY) Opdivo as adjuvant therapy for individuals with melanoma with the involvement of lymph nodes or metastatic disease who have undergone complete resection. The objective of the adjuvant therapy is to reduce the risk of recurrence after surgical removal of the tumor.
Pharma and biotech stocks made an impressive comeback in 2017 with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 18.7% and 11.8%, respectively. Immuno-oncology remains a key focus area with Gilead acquiring Kite last year for $11.9 billion and Celgene Corporation (NASDAQ:CELG) currently rumored to be interested in acquiring Juno Therapeutics Inc (NASDAQ:JUNO).
Novartis (NYSE: NVS) and Aeterna Zentaris Inc. (NASDAQ: AEZS) both saw spikes in volume and subsequent share price movement in the biotechnology and healthcare markets during the middle of this week. Here’s what happened with each and what comes next. Novartis This biotechnology behemoth reported on Wednesday that the US Food and Drug Administration (FDA) […] The post Here’s What’s Moving Novartis And Aeterna Zentaris Right Now appeared first on Market Exclusive.